Director of EU Industry & External Partnerships,
James has worked at GSK for the last 10 years on improving the way we develop and commercialise our products by working in partnership with stakeholders. Working collaboratively, he addresses significant health policy issues, often conducting pilots with stakeholders. For example, James led GSK’s engagement with EU payers, politicians and HTA agencies, under the European Healthcare Innovation Leadership “Tapestry” Network, which delivered the first multi-country parallel advice process. Building on this, he is currently working to improve patient access via Medicines Adaptive Pathways to Patients (MAPPs, or adaptive licensing). James participates in MIT’s NEWDIGS programme and leads much of GSK and EFPIA’s advocacy in this area and helps drive GSK’s pilot assets within the EMA AL programme. James also leads GSK advocacy in the area of Antimicrobial Resistance, launching the ground-breaking >€650m Innovative Medicines Initiative (IMI) AMR project with the EU Commission and participating in work with Chatham House, Brookings and UK Government programmes. Prior to this, James has held a number of Commercial roles at GSK and Shire Pharmaceuticals. James is Vice-Chair of the industry Healthcare Taskforce advising the OECD. He has a MBA from Harvard Business School and a Molecular Biology degree from Cambridge.